Lannett is one step closer to launching biosimilar insulin glargine. Recently, the company completed subject dosing in the pivotal clinical trial of biosimilar insulin glargine, a product being ...

LISBON, Portugal—Sanofi’s longer-acting basal insulin Toujeo, a follow-up to its own long-dominant product Lantus, beat the older medication at holding off hypoglycemia, both by day and by night. In ...

A 70-year-old man with a history of type 2 diabetes takes insulin glargine (Lantus) 100 units every morning (he is afraid of developing hypoglycemia at night) and insulin aspart (Novolog) 20 units ...

The designation means that pharmacists can switch patients to the less-expensive version of insulin without seeking approval from the clinician. The FDA late Thursday approved the country’s first ...

Novo Nordisk has long been working on drugs that can help people earlier on in their diabetes and keep them from progressing to insulin treatment. But that doesn’t mean it’s not also working to ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is working with Sanofi (NASDAQ: SNY), a global leader in ...

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased incidence ...

TREVOSE, Pa., Aug. 31, 2022 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that subject dosing has been completed in the pivotal clinical trial of biosimilar insulin glargine, a product ...